First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

TRAX Total Current Liabilities

All obligations due within one year.

First Tracks Biotherapeutics IncNASDAQ: TRAX

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities remains negative

Q1 FY2026 total current liabilities was $33.11M, compared with $0 a year earlier.

Context

  • Total current liabilities amounted to 11.4% of total assets at the end of Q1 FY2026.
  • Total current liabilities increased in 1 of the last 2 fiscal years.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.11M— QoQ
Last fiscal yearDec 2025
$31.02M-14.3% YoY
Year agoMar 2025
$0— since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-14.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
31.02M USD
Year-over-year change
-14.3%
2-year CAGR
+30.5%

Total Current Liabilities vs competitors

How TRAX compares with its peers on the latest reported figures

  • TRAX's Mar 2026 total current liabilities of $33.11M is the 5th highest of the 10 companies compared; the peer median is $27.37M.
  • Total current liabilities amounts to 11.4% of total assets for TRAX, versus a peer median of 11.5%.
TRAX Competitors Peer median
Total Current Liabilities for TRAX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMVTImmunovant, Inc.Sep 2026$104.02M +64.5%+34.1%13.7%
MLTXMoonLake ImmunotherapeuticsMar 2026$46.11M +92.3%+81.0%11.5%
ANABAnaptysBio, Inc.Mar 2026$41.7M -5.3%+14.0%12.6%
IMUXImmunic, Inc.Mar 2026$38.36M +49.9%+32.8%20.2%
TRAXFirst Tracks Biotherapeutics IncMar 2026$33.11M ——11.4%
ACRSAclaris Therapeutics, Inc.Mar 2026$27.37M +27.2%+9.3%13.8%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$13.46M +46.5%+41.5%9.2%
ATTOAttovia Therapeutics, Inc.Jun 2026$12.62M ——9.8%
SABSSAB Biotherapeutics, Inc.Jun 2026$11.71M +9.6%-10.7%4.9%
CLYMClimb Bio, Inc.Mar 2026$4.07M -42.1%+4.6%2.7%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding TRAX) $27.37M+36.9%+23.4%11.5%

Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents35.97M123.08M238.2M
Short-term Investments354.94M262.29M73.44M
Net Receivables000
Inventory000
Other Current Assets000
Total Current Assets398.56M389.93M316.4M
Property, Plant & Equipment (Net)18.27M16.23M13.89M
Goodwill000
Intangible Assets000
Long-term Investments27.03M35.47M0
Tax Assets000
Other Non-current Assets256K256K256K
Total Non-current Assets45.55M51.96M14.15M
Total Assets444.11M441.89M330.55M
Account Payables2.43M3.79M3.11M
Short-term Debt000
Tax Payables000
Deferred Revenue000
Other Current Liabilities4.59M7.42M0
Total Current Liabilities18.22M36.18M31.02M
Long-term Debt000
Deferred Tax Liabilities000
Deferred Revenue (Non-current)000
Other Non-current Liabilities000
Total Non-current Liabilities16.04M14.11M12.03M
Total Liabilities34.26M50.3M43.06M
Common Stock410.65M391.29M287.51M
Retained Earnings000
Accumulated OCI(797K)305K(24K)
Other Stockholders Equity000
Minority Interest000
Total Equity409.85M391.6M287.49M
Total Debt17.81M16.04M14.11M
Net Debt(18.15M)(107.04M)(224.08M)

First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Intrinsic Alpha fair value

Locked

Current Price

$44.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.